Government officials, National Assembly members, pharmaceutical and biotech companies, and research institutions will convene to explore global market entry strategies for the domestic bio-healthcare industry.
News1, a leading private news agency, is set to host the Global Bio Forum 2026 (GBF 2026) on November 10 at 8:30 a.m. (KST) in the Park Ballroom of the Conrad Seoul Hotel, Yeongdeungpo-gu, Seoul.
This year’s forum will center on the theme K-Bio and Healthcare: Embracing the Global Market. Attendees will examine strategies for international market entry, regulatory compliance, and approval processes in the domestic bio-healthcare sector. Discussions will also focus on enhancing competitiveness through innovative drug development and advanced medical devices. Key topics include artificial intelligence (AI) and stem cell-based drug development, as well as advancements in regenerative medicine.
The opening ceremony will feature remarks from Lee Young-seop, Chief Executive Officer (CEO) of News1, followed by congratulatory addresses from National Assembly Vice Chair Nam In-soon, Health and Welfare Committee Chair Lee Man-hee, Democratic Party lawmakers Seo Young-seok and Kim Gyo-heung, and Oh Yu-kyung, head of the Ministry of Food and Drug Safety.
The first session, titled K-New Drugs and Medical Devices: Exploring Global Innovations, will kick off with a keynote speech by Jeong Jae-ho, head of Yonsei University’s Convergence Science and Technology Institute. Dr. Jeong will explore how the integration of medicine, AI, and quantum computing is poised to revolutionize healthcare and drug development.
Keith Christopher, director at JNP Medi and former U.S. Food and Drug Administration (FDA) evaluator, will then present on Proactive Strategies for Global Clinical Trials, Approvals, and Market Entry.
Kim Beop-min, head of the Medical Device Research and Development Project at the Ministry of Health and Welfare, will discuss The Global Leap of K-Advanced Medical Devices: From R&D to Healthcare and Market.
Subsequent presentations will highlight new drug development and global expansion strategies from leading domestic pharmaceutical and biotech firms.
Kim Na-young, Vice President of Hanmi Pharmaceutical, will present on Innovations in Digital Convergence Pharmaceuticals Enabled by the Epi-TLS Platform. Choi Young-ki, Executive Director of Yuhan Corporation, will share insights on Lessons Learned During New Drug Development Through Open Innovation. Yang Eun-young, President of HLB Group’s Bio Business Development Division, will discuss Continuing the Success of New Drugs, Creating a Structure for Innovation, while Kang Dae-yeob, Vice President of SEERS, will present on The Connected Hospital Built by SEERS.
The morning session will conclude with a panel discussion on Regulations and Innovation: Challenges for K-New Drugs and Healthcare. Panelists will include the earlier speakers, with Park Mi-sun, PM of the K-Health Future Promotion Team, moderating the discussion.
The afternoon session, Stem Cells: Leading the Hope of K-Bio, will explore the future of advanced regenerative medicine and stem cell-based research.
Joseph C. Wu, Director of Stanford University’s Cardiovascular Institute and Professor of Cardiovascular Medicine and Radiology, will deliver the keynote address on New Approaches to Drug Development: Genomics, Stem Cells, and Artificial Intelligence, highlighting innovative methods in drug discovery.
Following this, Choi Kyung-il, a senior official at the Ministry of Health and Welfare, will outline Korea’s Policies and Support Directions for Advanced Regenerative Medicine. Park Jang-hwan, head of the Regenerative Medicine Technology Project, will then discuss The Role of the Project Team in Securing Innovative Technologies in Advanced Regenerative Medicine.
The corporate presentation (IR) session will feature Nam Yu-jun, Vice President of Ipsel, Lee Seung-hee, head of GSK Bio’s Research Institute, and Kim Mi-hyung, CEO of AntroGen, who will showcase their companies’ technologies and business strategies.
A panel discussion led by Park Jang-hwan will follow, featuring Professor Joseph C. Wu, Choi Kyung-il, Nam Yu-jun, and Lee Seung-hee. They will explore The New Possibilities of Stem Cells: Their Beginning and Future, addressing the trajectory of stem cell research, potential for commercializing advanced regenerative medicine, and challenges in translating research outcomes to clinical applications.
The GBF, organized by News1, is a premier forum that brings together government officials, lawmakers, industry leaders, and academics to assess the current state of the domestic bio-healthcare sector and chart its future course. It aims to address key industry issues and enhance the global competitiveness of Korean companies.
To register for the forum, please visit the
Global Bio Forum website (https://gbf.news1.kr/news/). For event-related inquiries, contact the Global Bio Forum Secretariat at 02-737-7026 or email news1biz@news1.kr.